tiprankstipranks
Trending News
More News >
PROCEPT BioRobotics (PRCT)
NASDAQ:PRCT
US Market
Advertisement

PROCEPT BioRobotics (PRCT) Stock Forecast & Price Target

Compare
564 Followers
See the Price Targets and Ratings of:

PRCT Analyst Ratings

Strong Buy
11Ratings
Strong Buy
10 Buy
1 Hold
0 Sell
Based on 11 analysts giving stock ratings to
PROCEPT
BioRobotics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PRCT Stock 12 Month Forecast

Average Price Target

$69.00
▲(77.29% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for PROCEPT BioRobotics in the last 3 months. The average price target is $69.00 with a high forecast of $85.00 and a low forecast of $55.00. The average price target represents a 77.29% change from the last price of $38.92.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"38":"$38","97":"$97","52.75":"$52.8","67.5":"$67.5","82.25":"$82.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$85.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":69,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$69.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$55.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[38,52.75,67.5,82.25,97],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.57,43.06461538461539,46.559230769230766,50.05384615384615,53.54846153846154,57.043076923076924,60.53769230769231,64.03230769230768,67.52692307692308,71.02153846153846,74.51615384615386,78.01076923076923,81.50538461538461,{"y":85,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.57,41.83384615384615,44.097692307692306,46.36153846153846,48.62538461538462,50.889230769230764,53.153076923076924,55.41692307692308,57.68076923076923,59.94461538461538,62.208461538461535,64.4723076923077,66.73615384615384,{"y":69,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.57,40.75692307692308,41.94384615384615,43.13076923076923,44.31769230769231,45.504615384615384,46.691538461538464,47.878461538461536,49.065384615384616,50.252307692307696,51.43923076923077,52.62615384615385,53.81307692307692,{"y":55,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":79,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.2,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.29,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.11,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.52,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.5,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.34,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.09,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.94,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.57,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.57,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$85.00Average Price Target$69.00Lowest Price Target$55.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TR | OpenAI - 4o Analyst forecast on PRCT
TR | OpenAI - 4o
TR | OpenAI - 4o
$41$39
Hold
0.21%
Upside
Reiterated
09/09/25
AI Generated ArticleAI Generated Article
Oppenheimer Analyst forecast on PRCT
Oppenheimer
Oppenheimer
$60
Buy
54.16%
Upside
Upgraded
09/02/25
Procept BioRobotics upgraded to Outperform from Perform at OppenheimerProcept BioRobotics upgraded to Outperform from Perform at Oppenheimer
William Blair Analyst forecast on PRCT
William Blair
William Blair
Buy
Reiterated
08/18/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Morgan Stanley Analyst forecast on PRCT
Morgan Stanley
Morgan Stanley
$68$62
Buy
59.30%
Upside
Reiterated
08/08/25
PROCEPT BioRobotics (PRCT) Gets a Buy from Morgan StanleyMorgan Stanley analyst Patrick Wood lowered the price target on Procept BioRobotics Corp (NASDAQ: PRCT) to $62.00 (from $68.00) while maintaining a Overweight rating.
Truist Financial Analyst forecast on PRCT
Truist Financial
Truist Financial
$70$64
Buy
64.44%
Upside
Reiterated
08/07/25
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT), Amgen (NASDAQ: AMGN) and Qiagen (NYSE: QGEN)
Leerink Partners Analyst forecast on PRCT
Leerink Partners
Leerink Partners
$83
Buy
113.26%
Upside
Reiterated
08/07/25
Buy Rating for PROCEPT BioRobotics: Growth Potential and Stability Amid Sales Beat and Improved Guidance
Wells Fargo Analyst forecast on PRCT
Wells Fargo
Wells Fargo
$75$58
Buy
49.02%
Upside
Reiterated
08/07/25
Wells Fargo Reaffirms Their Buy Rating on PROCEPT BioRobotics (PRCT)
BTIG
Hold
Reiterated
08/07/25
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT) and Enovis (NYSE: ENOV)
Piper Sandler Analyst forecast on PRCT
Piper Sandler
Piper Sandler
$80$55
Buy
41.32%
Upside
Reiterated
08/07/25
Procept BioRobotics price target lowered to $55 from $80 at Piper SandlerProcept BioRobotics price target lowered to $55 from $80 at Piper Sandler
TD Cowen
$85
Buy
118.40%
Upside
Reiterated
08/06/25
TD Cowen Reaffirms Their Buy Rating on PROCEPT BioRobotics (PRCT)
Bank of America Securities Analyst forecast on PRCT
Bank of America Securities
Bank of America Securities
$84
Buy
115.83%
Upside
Reiterated
07/15/25
Positive Outlook on PROCEPT BioRobotics Amid New Fee Schedule Developments for Aquablation
Stephens
$70
Buy
79.86%
Upside
Initiated
07/09/25
Procept BioRobotics initiated with an Overweight at StephensProcept BioRobotics initiated with an Overweight at Stephens
Jefferies
Hold
Reiterated
05/02/25
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT), Intuitive Surgical (NASDAQ: ISRG) and Bio-Rad Laboratories (NYSE: BIO)
TD Securities Analyst forecast on PRCT
Unknown Analyst
TD Securities
Not Ranked
TD Securities
$99$85
Buy
118.40%
Upside
Reiterated
02/26/25
Lowering PT to $85 from $99.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TR | OpenAI - 4o Analyst forecast on PRCT
TR | OpenAI - 4o
TR | OpenAI - 4o
$41$39
Hold
0.21%
Upside
Reiterated
09/09/25
AI Generated ArticleAI Generated Article
Oppenheimer Analyst forecast on PRCT
Oppenheimer
Oppenheimer
$60
Buy
54.16%
Upside
Upgraded
09/02/25
Procept BioRobotics upgraded to Outperform from Perform at OppenheimerProcept BioRobotics upgraded to Outperform from Perform at Oppenheimer
William Blair Analyst forecast on PRCT
William Blair
William Blair
Buy
Reiterated
08/18/25
Wall Street Analysts Are Bullish on Top Healthcare Picks
Morgan Stanley Analyst forecast on PRCT
Morgan Stanley
Morgan Stanley
$68$62
Buy
59.30%
Upside
Reiterated
08/08/25
PROCEPT BioRobotics (PRCT) Gets a Buy from Morgan StanleyMorgan Stanley analyst Patrick Wood lowered the price target on Procept BioRobotics Corp (NASDAQ: PRCT) to $62.00 (from $68.00) while maintaining a Overweight rating.
Truist Financial Analyst forecast on PRCT
Truist Financial
Truist Financial
$70$64
Buy
64.44%
Upside
Reiterated
08/07/25
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT), Amgen (NASDAQ: AMGN) and Qiagen (NYSE: QGEN)
Leerink Partners Analyst forecast on PRCT
Leerink Partners
Leerink Partners
$83
Buy
113.26%
Upside
Reiterated
08/07/25
Buy Rating for PROCEPT BioRobotics: Growth Potential and Stability Amid Sales Beat and Improved Guidance
Wells Fargo Analyst forecast on PRCT
Wells Fargo
Wells Fargo
$75$58
Buy
49.02%
Upside
Reiterated
08/07/25
Wells Fargo Reaffirms Their Buy Rating on PROCEPT BioRobotics (PRCT)
BTIG
Hold
Reiterated
08/07/25
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT) and Enovis (NYSE: ENOV)
Piper Sandler Analyst forecast on PRCT
Piper Sandler
Piper Sandler
$80$55
Buy
41.32%
Upside
Reiterated
08/07/25
Procept BioRobotics price target lowered to $55 from $80 at Piper SandlerProcept BioRobotics price target lowered to $55 from $80 at Piper Sandler
TD Cowen
$85
Buy
118.40%
Upside
Reiterated
08/06/25
TD Cowen Reaffirms Their Buy Rating on PROCEPT BioRobotics (PRCT)
Bank of America Securities Analyst forecast on PRCT
Bank of America Securities
Bank of America Securities
$84
Buy
115.83%
Upside
Reiterated
07/15/25
Positive Outlook on PROCEPT BioRobotics Amid New Fee Schedule Developments for Aquablation
Stephens
$70
Buy
79.86%
Upside
Initiated
07/09/25
Procept BioRobotics initiated with an Overweight at StephensProcept BioRobotics initiated with an Overweight at Stephens
Jefferies
Hold
Reiterated
05/02/25
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (NASDAQ: PRCT), Intuitive Surgical (NASDAQ: ISRG) and Bio-Rad Laboratories (NYSE: BIO)
TD Securities Analyst forecast on PRCT
Unknown Analyst
TD Securities
Not Ranked
TD Securities
$99$85
Buy
118.40%
Upside
Reiterated
02/26/25
Lowering PT to $85 from $99.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering PROCEPT BioRobotics

1 Month
xxx
Success Rate
9/11 ratings generated profit
82%
Average Return
+12.98%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 81.82% of your transactions generating a profit, with an average return of +12.98% per trade.
3 Months
xxx
Success Rate
9/12 ratings generated profit
75%
Average Return
+14.84%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +14.84% per trade.
1 Year
Matthew O'BrienPiper Sandler
Success Rate
6/11 ratings generated profit
55%
Average Return
+24.50%
reiterated a buy rating last month
Copying Matthew O'Brien's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +24.50% per trade.
2 Years
xxx
Success Rate
12/24 ratings generated profit
50%
Average Return
+12.06%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +12.06% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PRCT Analyst Recommendation Trends

Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
5
5
1
5
6
Buy
9
11
16
19
15
Hold
9
11
17
19
15
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
23
27
34
43
36
In the current month, PRCT has received 21 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. PRCT average Analyst price target in the past 3 months is 69.00.
Each month's total comprises the sum of three months' worth of ratings.

PRCT Financial Forecast

PRCT Earnings Forecast

Next quarter’s earnings estimate for PRCT is -$0.41 with a range of -$0.45 to -$0.35. The previous quarter’s EPS was -$0.35. PRCT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year PRCT has Outperformed its overall industry.
Next quarter’s earnings estimate for PRCT is -$0.41 with a range of -$0.45 to -$0.35. The previous quarter’s EPS was -$0.35. PRCT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year PRCT has Outperformed its overall industry.

PRCT Sales Forecast

Next quarter’s sales forecast for PRCT is $80.85M with a range of $79.63M to $82.05M. The previous quarter’s sales results were $79.18M. PRCT beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 73.68% of the time in the same period. In the last calendar year PRCT has Outperformed its overall industry.
Next quarter’s sales forecast for PRCT is $80.85M with a range of $79.63M to $82.05M. The previous quarter’s sales results were $79.18M. PRCT beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 73.68% of the time in the same period. In the last calendar year PRCT has Outperformed its overall industry.

PRCT Stock Forecast FAQ

What is PRCT’s average 12-month price target, according to analysts?
Based on analyst ratings, PROCEPT BioRobotics’s 12-month average price target is 69.00.
    What is PRCT’s upside potential, based on the analysts’ average price target?
    PROCEPT BioRobotics has 77.29% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PRCT a Buy, Sell or Hold?
          PROCEPT BioRobotics has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.
            What is PROCEPT BioRobotics’s price target?
            The average price target for PROCEPT BioRobotics is 69.00. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $85.00 ,the lowest forecast is $55.00. The average price target represents 77.29% Increase from the current price of $38.92.
              What do analysts say about PROCEPT BioRobotics?
              PROCEPT BioRobotics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of PRCT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis